Explora BioLabs provides biopharmaceutical clients with turnkey in vivo vivarium facilities, management, and related services to facilitate early-stage research activities. The company, which has over 100 employees, currently operates more than 15 preclinical vivarium facilities in the Southern California, San Francisco, and Boston-Cambridge biohubs, with a planned expansion in Seattle in 2022.

The acquisition of Explora BioLabs complements and expands the Charles River Accelerator and Development Lab operation, which is part of Charles River's Insourcing Solutions business.

Charles River expands strategic partnership with SAMDI Tech
Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless...

Charles River, Valo Health announce strategic partnership
Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence-enabled drug...

Charles River to partner with ATEM Structural Discovery
Charles River Laboratories International has inked a partnership with ATEM Structural Discovery to provide its clients with ATEM's cryoelectron microscopy...

Charles River completes Vigene acquisition
Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction...

Charles River to acquire Vigene Biosciences for $293M
Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing...